Subjects: ANGIOTENSINAS, GLOMERUNEFRITE, INSUFICIÊNCIA RENAL CRÔNICA, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROVIN, Brad H et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. LANCET, v. 402, n. 10417, p. 2077-2090, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57858. Acesso em: 02 out. 2024.APA
Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D. -W., et al. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. LANCET, 402( 10417), 2077-2090. doi:10.1016/S0140-6736(23)02302-4NLM
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D-W, Diva UA, Floege J, Gesualdo L, Inrig JK, Noronha I de L. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial [Internet]. LANCET. 2023 ; 402( 10417): 2077-2090.[citado 2024 out. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57858Vancouver
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D-W, Diva UA, Floege J, Gesualdo L, Inrig JK, Noronha I de L. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial [Internet]. LANCET. 2023 ; 402( 10417): 2077-2090.[citado 2024 out. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57858